Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 50 min ago
Peer-reviewedLicence not statedJournal of Clinical Oncology

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study

  • Muhammad Adnan Khattak1
  • Matteo Salvatore Carlino2
  • Tarek M. Meniawy3
  • George Ansstas4
  • Matthew H. Taylor5
  • Kevin B. Kim6
  • Meredith Ann McKean7
  • Georgina Venetia Long8
  • Ryan Joseph Sullivan9
  • Mark B. Faries10
  • Thuy Thanh Thi Tran11
  • C. Lance Cowey12
10 more authors
  • Andrew Pecora13
  • Theresa M. Medina14
  • Victoria G. Atkinson15
  • Clemens Krepler16
  • Thomas Jemielita16
  • Huzhang Mao17
  • Jacky Louis Chow17
  • Laureen S. Ojalvo17
  • Janice M. Mehnert18
  • on behalf of the KEYNOTE-942 Investigators
18 affiliations
  1. 1One Clinical Research, Hollywood Private Hospital and Edith Cowan University, Perth, WA, Australia
  2. 2Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, NSW, Australia
  3. 3Saint John of God Subiaco Hospital, Subiaco, WA, Australia
  4. 4Washington University School of Medicine, St Louis, MO
  5. 5Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR
  6. 6California Pacific Medical Center Research Institute, San Francisco, CA
  7. 7Sarah Cannon Research Institute, Nashville, TN
  8. 8Melanoma Institute Australia, Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, NSW, Australia
  9. 9Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA
  10. 10The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA
  11. 11Smilow Cancer Center at Yale New Haven Hospital, New Haven, CT
  12. 12Texas Oncology PA, Dallas, TX
  13. 13Hackensack University Medical Center, Hackensack, NJ
  14. 14University of Colorado Cancer Center, Aurora, CO
  15. 15Princess Alexandra Hospital, Brisbane, QLD, Australia
  16. 16Merck & Co, Inc, Rahway, NJ
  17. 17Moderna, Inc, Cambridge, MA
  18. 18Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY
Open at sourcePDFDOICite

Related

  1. Updated outcomes of AdjuMel study: real-world data in patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France
    S. Dalle, P. Saiag, C. Lebbé +13
    European journal of cancer skin cancerPeer-reviewedCC BY-NC-ND 4.0Full text1 citedImmunologyEpidemiology & public healthHAL
  2. Isolated Adrenocorticotropic Hormone Deficiency Secondary to Pembrolizumab-Induced Hypophysitis: A Case of Life-Threatening Adrenal Crisis in a Patient With Metastatic Melanoma
    Tashbaev Sherzodbek, Mamatov Hurshidbek Mirzakamol o‘g‘li, Azizbek Mutalipov +4
    Clinical Medicine Insights: Endocrinology and DiabetesPeer-reviewedCC BYFull textEndocrinology & metabolismDOAJ
  3. Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMel
    Stéphane Dalle, Philippe Saiag, Céleste Lebbé +12
    Dermatology and TherapyPeer-reviewedCC BY-NC 4.0Full textOncologyHAL
  4. Enhanced melanoma-specific cytotoxic T-cell expansion and the clinical outcomes with simlukafusp alfa and pembrolizumab following checkpoint inhibitor progression
    Fabian Junker, Martine Darwish, Mahesh Yadav +10
    Journal for Immunotherapy of CancerPeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  5. Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial
    Hideaki Bando, Jun Watanabe, Yusuke Takahashi +31
    Nature MedicinePeer-reviewedCC BY-NC-NDFull text18 citedOncologyOpenAlex

Cite

BibTeXRIS
BibTeX
@article{khattak2026intismeran,
  title = {{Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study}},
  author = {Muhammad Adnan Khattak and Matteo Salvatore Carlino and Tarek M. Meniawy and George Ansstas and Matthew H. Taylor and Kevin B. Kim and Meredith Ann McKean and Georgina Venetia Long and Ryan Joseph Sullivan and Mark B. Faries and Thuy Thanh Thi Tran and C. Lance Cowey and Andrew Pecora and Theresa M. Medina and Victoria G. Atkinson and Clemens Krepler and Thomas Jemielita and Huzhang Mao and Jacky Louis Chow and Laureen S. Ojalvo and Janice M. Mehnert and on behalf of the KEYNOTE-942 Investigators},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  month = jun,
  doi = {10.1200/jco-26-00835},
  url = {https://doi.org/10.1200/jco-26-00835},
}
RIS
TY  - JOUR
TI  - Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study
AU  - Muhammad Adnan Khattak
AU  - Matteo Salvatore Carlino
AU  - Tarek M. Meniawy
AU  - George Ansstas
AU  - Matthew H. Taylor
AU  - Kevin B. Kim
AU  - Meredith Ann McKean
AU  - Georgina Venetia Long
AU  - Ryan Joseph Sullivan
AU  - Mark B. Faries
AU  - Thuy Thanh Thi Tran
AU  - C. Lance Cowey
AU  - Andrew Pecora
AU  - Theresa M. Medina
AU  - Victoria G. Atkinson
AU  - Clemens Krepler
AU  - Thomas Jemielita
AU  - Huzhang Mao
AU  - Jacky Louis Chow
AU  - Laureen S. Ojalvo
AU  - Janice M. Mehnert
AU  - on behalf of the KEYNOTE-942 Investigators
PY  - 2026
DA  - 2026/06/01
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco-26-00835
UR  - https://doi.org/10.1200/jco-26-00835
SN  - 0732-183X
SN  - 1527-7755
ER  -